The transcatheter aortic valve replacement team completed one year of service in July 2016. They have performed 39/39 successful TAVR procedures. Look for TAVR outcomes data this winter.
The FDA recently expanded indications for TAVR to include intermediate risk patients. This new approval significantly increase the number of eligible patients. Information will be distributed to physicians soon.